Company news
Savara, Inc. news in 2019
Savara, Inc.'s news releases, calls and decks from 2019, newest first.
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
December 29, 2019
Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million
December 19, 2019
Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors
December 2, 2019
Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference
November 25, 2019
Savara Appoints Badrul Chowdhury, M.D., Ph.D as Chief Medical Officer
November 17, 2019
Savara to Present at the Stifel 2019 Healthcare Conference
November 11, 2019
Savara Reports Third Quarter 2019 Financial Results and Provides Business Update
November 6, 2019
Savara to Report Third Quarter 2019 Financial Results and Provide Business Update
October 30, 2019
Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program
October 1, 2019
Savara to Present Comprehensive Data From Pivotal Phase 3 IMPALA Study at 2019 ERS
September 17, 2019
Decks in 2019
- Technical Presentation (October 2019)
Technical · 25 slides · Oct 2, 2019